University of Hertfordshire

From the same journal

By the same authors

Standard

Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women. / Gentry-Maharaj, Aleksandra; Blyuss, Oleg; Ryan, Andy; Burnell, Matthew; Karpinskyj, Chloe; Gunu, Richard; Kalsi, Jatinderpal K.; Dawnay, Anne; Marino, Ines P.; Manchanda, Ranjit; Lu, Karen; Yang, Wei Lei; Timms, John F.; Parmar, Max; Skates, Steven J.; Bast, Robert C.; Jacobs, Ian J.; Zaikin, Alexey; Menon, Usha.

In: Cancers, Vol. 12, No. 7, 1931, 07.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

Gentry-Maharaj, A, Blyuss, O, Ryan, A, Burnell, M, Karpinskyj, C, Gunu, R, Kalsi, JK, Dawnay, A, Marino, IP, Manchanda, R, Lu, K, Yang, WL, Timms, JF, Parmar, M, Skates, SJ, Bast, RC, Jacobs, IJ, Zaikin, A & Menon, U 2020, 'Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women', Cancers, vol. 12, no. 7, 1931. https://doi.org/10.3390/cancers12071931

APA

Gentry-Maharaj, A., Blyuss, O., Ryan, A., Burnell, M., Karpinskyj, C., Gunu, R., Kalsi, J. K., Dawnay, A., Marino, I. P., Manchanda, R., Lu, K., Yang, W. L., Timms, J. F., Parmar, M., Skates, S. J., Bast, R. C., Jacobs, I. J., Zaikin, A., & Menon, U. (2020). Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women. Cancers, 12(7), [1931]. https://doi.org/10.3390/cancers12071931

Vancouver

Author

Gentry-Maharaj, Aleksandra ; Blyuss, Oleg ; Ryan, Andy ; Burnell, Matthew ; Karpinskyj, Chloe ; Gunu, Richard ; Kalsi, Jatinderpal K. ; Dawnay, Anne ; Marino, Ines P. ; Manchanda, Ranjit ; Lu, Karen ; Yang, Wei Lei ; Timms, John F. ; Parmar, Max ; Skates, Steven J. ; Bast, Robert C. ; Jacobs, Ian J. ; Zaikin, Alexey ; Menon, Usha. / Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women. In: Cancers. 2020 ; Vol. 12, No. 7.

Bibtex

@article{ec7a28822cf440aeb37b9acdc8b956dd,
title = "Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women",
abstract = "Longitudinal CA125 algorithms are the current basis of ovarian cancer screening. We report on longitudinal algorithms incorporating multiple markers. In the multimodal arm of United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), 50,640 postmenopausal women underwent annual screening using a serum CA125 longitudinal algorithm. Women (cases) with invasive tubo-ovarian cancer (WHO 2014) following outcome review with stored annual serum samples donated in the 5 years preceding diagnosis were matched 1:1 to controls (no invasive tubo-ovarian cancer) in terms of the number of annual samples and age at randomisation. Blinded samples were assayed for serum human epididymis protein 4 (HE4), CA72-4 and anti-TP53 autoantibodies. Multimarker method of mean trends (MMT) longitudinal algorithms were developed using the assay results and trial CA125 values on the training set and evaluated in the blinded validation set. The study set comprised of 1363 (2–5 per woman) serial samples from 179 cases and 181 controls. In the validation set, area under the curve (AUC) and sensitivity of longitudinal CA125-MMT algorithm were 0.911 (0.871–0.952) and 90.5% (82.5–98.6%). None of the longitudinal multi-marker algorithms (CA125-HE4, CA125-HE4-CA72-4, CA125-HE4-CA72-4-anti-TP53) performed better or improved on lead-time. Our population study suggests that longitudinal HE4, CA72-4, anti-TP53 autoantibodies adds little value to longitudinal serum CA125 as a first-line test in ovarian cancer screening of postmenopausal women.",
keywords = "CA125, HE4, MMT, Ovarian cancer, Postmenopausal women, Screening, UKCTOCS",
author = "Aleksandra Gentry-Maharaj and Oleg Blyuss and Andy Ryan and Matthew Burnell and Chloe Karpinskyj and Richard Gunu and Kalsi, {Jatinderpal K.} and Anne Dawnay and Marino, {Ines P.} and Ranjit Manchanda and Karen Lu and Yang, {Wei Lei} and Timms, {John F.} and Max Parmar and Skates, {Steven J.} and Bast, {Robert C.} and Jacobs, {Ian J.} and Alexey Zaikin and Usha Menon",
note = "{\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).",
year = "2020",
month = jul,
doi = "10.3390/cancers12071931",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI",
number = "7",

}

RIS

TY - JOUR

T1 - Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women

AU - Gentry-Maharaj, Aleksandra

AU - Blyuss, Oleg

AU - Ryan, Andy

AU - Burnell, Matthew

AU - Karpinskyj, Chloe

AU - Gunu, Richard

AU - Kalsi, Jatinderpal K.

AU - Dawnay, Anne

AU - Marino, Ines P.

AU - Manchanda, Ranjit

AU - Lu, Karen

AU - Yang, Wei Lei

AU - Timms, John F.

AU - Parmar, Max

AU - Skates, Steven J.

AU - Bast, Robert C.

AU - Jacobs, Ian J.

AU - Zaikin, Alexey

AU - Menon, Usha

N1 - © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PY - 2020/7

Y1 - 2020/7

N2 - Longitudinal CA125 algorithms are the current basis of ovarian cancer screening. We report on longitudinal algorithms incorporating multiple markers. In the multimodal arm of United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), 50,640 postmenopausal women underwent annual screening using a serum CA125 longitudinal algorithm. Women (cases) with invasive tubo-ovarian cancer (WHO 2014) following outcome review with stored annual serum samples donated in the 5 years preceding diagnosis were matched 1:1 to controls (no invasive tubo-ovarian cancer) in terms of the number of annual samples and age at randomisation. Blinded samples were assayed for serum human epididymis protein 4 (HE4), CA72-4 and anti-TP53 autoantibodies. Multimarker method of mean trends (MMT) longitudinal algorithms were developed using the assay results and trial CA125 values on the training set and evaluated in the blinded validation set. The study set comprised of 1363 (2–5 per woman) serial samples from 179 cases and 181 controls. In the validation set, area under the curve (AUC) and sensitivity of longitudinal CA125-MMT algorithm were 0.911 (0.871–0.952) and 90.5% (82.5–98.6%). None of the longitudinal multi-marker algorithms (CA125-HE4, CA125-HE4-CA72-4, CA125-HE4-CA72-4-anti-TP53) performed better or improved on lead-time. Our population study suggests that longitudinal HE4, CA72-4, anti-TP53 autoantibodies adds little value to longitudinal serum CA125 as a first-line test in ovarian cancer screening of postmenopausal women.

AB - Longitudinal CA125 algorithms are the current basis of ovarian cancer screening. We report on longitudinal algorithms incorporating multiple markers. In the multimodal arm of United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), 50,640 postmenopausal women underwent annual screening using a serum CA125 longitudinal algorithm. Women (cases) with invasive tubo-ovarian cancer (WHO 2014) following outcome review with stored annual serum samples donated in the 5 years preceding diagnosis were matched 1:1 to controls (no invasive tubo-ovarian cancer) in terms of the number of annual samples and age at randomisation. Blinded samples were assayed for serum human epididymis protein 4 (HE4), CA72-4 and anti-TP53 autoantibodies. Multimarker method of mean trends (MMT) longitudinal algorithms were developed using the assay results and trial CA125 values on the training set and evaluated in the blinded validation set. The study set comprised of 1363 (2–5 per woman) serial samples from 179 cases and 181 controls. In the validation set, area under the curve (AUC) and sensitivity of longitudinal CA125-MMT algorithm were 0.911 (0.871–0.952) and 90.5% (82.5–98.6%). None of the longitudinal multi-marker algorithms (CA125-HE4, CA125-HE4-CA72-4, CA125-HE4-CA72-4-anti-TP53) performed better or improved on lead-time. Our population study suggests that longitudinal HE4, CA72-4, anti-TP53 autoantibodies adds little value to longitudinal serum CA125 as a first-line test in ovarian cancer screening of postmenopausal women.

KW - CA125

KW - HE4

KW - MMT

KW - Ovarian cancer

KW - Postmenopausal women

KW - Screening

KW - UKCTOCS

UR - http://www.scopus.com/inward/record.url?scp=85088169402&partnerID=8YFLogxK

U2 - 10.3390/cancers12071931

DO - 10.3390/cancers12071931

M3 - Article

AN - SCOPUS:85088169402

VL - 12

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 7

M1 - 1931

ER -